Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 16.09 is 60% above its 5-year average of 10.04, around the middle of its 5-year range (1.18–28.05).
As of the fiscal period ended Tuesday, June 30, 2026. 10.64% above its 12-month average of 14.55.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.09.
QUICK RATIO (ACID-TEST)
16.09
QUICK RATIO (ACID-TEST) AVG TTM
14.55
QUICK RATIO (ACID-TEST) AVG 3Y
5.87
QUICK RATIO (ACID-TEST) AVG 5Y
10.04
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.64%
CURRENT VS 3Y AVG
+174.30%
CURRENT VS 5Y AVG
+60.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.83
median of 446 covered companies
CURRENT VS SECTOR MEDIAN
+469.71%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$749.55M
Quick Ratio (Acid-Test)
16.09
TTM Avg
14.55
3Y Avg
5.87
5Y Avg
10.04
Market Cap
$734.10M
Quick Ratio (Acid-Test)
14.20
TTM Avg
2.59
3Y Avg
2.42
5Y Avg
2.06
Market Cap
$767.46M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$774.32M
Quick Ratio (Acid-Test)
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
Market Cap
$775.72M
Quick Ratio (Acid-Test)
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$776.24M
Quick Ratio (Acid-Test)
5.16
TTM Avg
4.89
3Y Avg
3.82
5Y Avg
4.31
Market Cap
$719.64M
Quick Ratio (Acid-Test)
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$780.95M
Quick Ratio (Acid-Test)
0.98
TTM Avg
0.95
3Y Avg
0.97
5Y Avg
0.95
Market Cap
$786.48M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.81
3Y Avg
5.95
5Y Avg
7.14
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $749.55M | 16.09 | 14.55 | 5.87 | 10.04 |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | 14.20 | 2.59 | 2.42 | 2.06 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | 19.31 | 14.05 | 7.67 | 5.91 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | 9.39 | 11.79 | 11.79 | 11.79 |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 18.86 | 23.23 | 26.78 | 32.61 |
| Geron Corporation (GERN)vs › | $776.24M | 5.16 | 4.89 | 3.82 | 4.31 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | 0.95 | 4.92 | 2.98 | 5.72 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 0.98 | 0.95 | 0.97 | 0.95 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | 3.86 | 4.81 | 5.95 | 7.14 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 0.84 | 1.18 | 1.08 | 1.08 |
Quick Ratio
16.09
Excludes inventory
Current Ratio
16.09
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 16.09 |
| 2026-03-31 | 28.05 |
| 2025-12-31 | 13.31 |
| 2025-09-30 | 8.25 |
| 2025-06-30 | 7.04 |
| 2025-03-31 | 4.64 |
| 2024-12-31 | 2.77 |
| 2024-09-30 | 1.18 |
| 2024-06-30 | 1.62 |
| 2024-03-31 | 2.00 |
| 2023-12-31 | 2.59 |
| 2023-09-30 | 4.37 |
| 2023-06-30 | 6.54 |
| 2023-03-31 | 11.82 |
| 2022-12-31 | 12.81 |
| 2022-09-30 | 13.41 |
| 2022-06-30 | 14.86 |
| 2022-03-31 | 17.48 |
| 2021-12-31 | 15.84 |
| 2021-09-30 | 20.68 |
| 2021-06-30 | 5.44 |
| 2021-03-31 | 5.36 |
| 2020-12-31 | 7.46 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
